Abiopharma

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Results of Meeting

Thermo Fisher Scientific - Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Align Technology Announces Invisalign® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction

Ryoncil Revenue Growth Highlighted in AGM Trading Update

CEO Presentation to 2025 Annual General Meeting

Mesoblast Chair Message to 2025 AGM

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

GE HealthCare announces cash dividend for fourth quarter of 2025

GE HealthCare announces cash dividend for fourth quarter of 2025